LRRC8E

Across TCGA pan-cancer cohorts, LRRC8E Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LRRC8E data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher LRRC8E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC8E expression acts as an unfavorable survival marker.

THYM, HNSC, and SARC are the cancer types where LRRC8E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
HNSC	OS	Median	All	0.051	0.711	<.001	24	view →
SARC	DFS	Median	All	0.094	0.611	.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	All	0.181	0.806	.002	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	OS	Median	All	0.350	0.799	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LRRC8E–THYM (OS)

Open the THYM breakdown →